Diagnostic Workup for Hemolytic Anemia
Begin with laboratory confirmation of hemolysis using reticulocyte count, lactate dehydrogenase (LDH), indirect bilirubin, and haptoglobin, then immediately perform a direct antiglobulin test (DAT/Coombs test) to differentiate autoimmune from non-autoimmune causes 1, 2.
Initial Laboratory Evaluation
The diagnostic approach requires specific hemolytic markers in this order:
- Reticulocyte count: Elevated indicates compensatory marrow response (though 20-40% of autoimmune cases show reticulocytopenia, which is a poor prognostic sign) 2
- LDH: Markedly elevated, especially in intravascular hemolysis 1, 2
- Haptoglobin: Decreased or absent 1, 2
- Indirect bilirubin: Elevated 1, 2
- Blood smear examination: Critical for identifying fragmented RBCs (schistocytes) suggesting thrombotic microangiopathy, or membrane defects 1, 2
Critical pitfall: Reticulocytopenia occurs in 20-40% of autoimmune hemolytic anemia cases due to marrow involvement, iron/vitamin deficiency, infections, or autoimmune reaction against bone marrow precursors—this does not exclude hemolysis 2.
The DAT: Your Diagnostic Branch Point
The direct antiglobulin test is the cornerstone that determines your entire diagnostic and treatment pathway 1, 3, 4.
DAT-Positive Patterns Guide Classification:
- IgG positive (±C3d): Warm autoimmune hemolytic anemia (wAIHA)—most common type 3, 4, 5
- C3d positive only: Cold agglutinin disease/syndrome (CAD/CAS) or paroxysmal cold hemoglobinuria (PCH) 3, 4, 5
- Both IgG and C3d positive: Mixed AIHA 5
- DAT negative with hemolysis: Consider DAT-negative AIHA (antibody below detection threshold), drug-induced hemolytic anemia, or non-immune causes 5
DAT-Negative Hemolysis Requires Different Workup:
Look for fragmentation syndromes by examining the blood smear for schistocytes plus thrombocytopenia, suggesting hemolytic uremic syndrome or thrombotic thrombocytopenic purpura 1. Check for hemosiderinuria and markedly elevated LDH indicating intravascular hemolysis as seen in paroxysmal nocturnal hemoglobinuria 2. Consider hereditary causes requiring enzyme assays (pyruvate kinase deficiency) or hemoglobin electrophoresis for hemoglobinopathies 6, 7.
Important caveat: Pyruvate kinase deficiency diagnosis is notoriously difficult—only 4 out of 17 patients were diagnosed correctly in laboratory surveys, requiring specialized enzyme assays and potentially genetic testing 6.
Additional Diagnostic Considerations
- Hemoglobin level: Defines clinical severity 2
- Platelet count: Thrombocytopenia suggests thrombotic microangiopathy or Evans' syndrome 2
- Hemosiderinuria: Typical of chronic intravascular hemolysis 2
- Hyperferritinemia: Associated with chronic hemolysis 2
Search for underlying conditions in wAIHA (present in ~50% of cases) and always identify secondary causes in cold agglutinin syndrome 3, 4.
Treatment Approach
Treatment is entirely cause-dependent—there is no generic treatment for hemolytic anemia, making accurate diagnosis mandatory before initiating therapy 8.
Warm Autoimmune Hemolytic Anemia (wAIHA)
First-line: Corticosteroids, with rituximab as steroid-sparing agent 3, 4, 5. Consider IVIG or monoclonal antibodies to CD20, CD38, or C1q for refractory cases 5. Splenectomy is a historical option but has been largely replaced by targeted therapies 4.
Cold Agglutinin Disease (CAD)
First-line: Rituximab ± bendamustine 3, 4. Sutimlimab (anti-C1s complement inhibitor) represents a major therapeutic advance and is now an approved option for CAD requiring treatment 3, 4. Keep patients warm as foundational management 5. Consider monoclonal antibodies against C1q or C5 for significant complement-mediated outcomes 5.
Mixed AIHA
Use treatment approaches appropriate for both wAIHA and cold AIHA components 5.
Paroxysmal Cold Hemoglobinuria (PCH)
Usually self-remitting, but may consider monoclonal antibodies to C1q or C5 if intervention needed 5.
Thrombotic Microangiopathies
Critical pitfall to avoid: Do NOT transfuse platelets early in thrombotic thrombocytopenic purpura 9. Emergency resuscitation takes priority, but recognize the hemolytic process and obtain appropriate specialist consultation immediately 9.
Drug-Induced Immune Hemolytic Anemia
Appears as wAIHA; some cases resolve after discontinuing the offending drug 5.
The emergency physician must first resuscitate but simultaneously recognize hemolysis is present, obtain appropriate laboratory tests, and involve hematology consultation early 9.